PLA2G7 and coronary artery disorder: Mohler et al. [57] tested the effects of darapladib (40, 80 and 160 mg, respectively) on Lp-PLA2 activity and on biomarkers of CV risk in 959 CHD and CHD-risk equivalent patients receiving aggressive lipid-lowering therapy (atorvastatin 20 or 80 mg per day) (NCT00269048).